Difference between revisions of "Bleomycin (Blenoxane)"
(Created page with "'''1 unit of bleomycin = 1 mg of bleomycin'''") |
m |
||
| Line 1: | Line 1: | ||
| − | + | ==General information== | |
| + | Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and | ||
| + | protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.<ref name="insert">[http://www.bmscanada.ca/static/products/en/pm_pdf/Blenoxane_E_PM_3%20DEC%2010_APP_CLN.pdf Bleomycin (Blenoxane) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/bleomycin.pdf Bleomycin (Blenoxane) package insert (locally hosted backup)]</ref> | ||
| + | <br>Route: IV, IM, SC, intrapleural | ||
| + | <br>1 unit of bleomycin = 1 mg of bleomycin | ||
| + | <br>Extravasation: [[irritant]] | ||
| + | |||
| + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *[http://www.uptodate.com/contents/bleomycin-patient-drug-information Bleomycin (Blenoxane) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bleomycin-patient-drug-information Bleomycin (Blenoxane) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Regimens== | ||
| + | Standard format will be: | ||
| + | <br><acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease) | ||
| + | |||
| + | ==References== | ||
| + | <references/> | ||
Revision as of 16:53, 29 November 2011
General information
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and
protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1][2]
Route: IV, IM, SC, intrapleural
1 unit of bleomycin = 1 mg of bleomycin
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
Regimens
Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)